ScandiDos AB (SDOS) Fair Value & Analysis
Healthcare · SE · Market cap 51.0M SEK
Fair value as of: Jul 18, 2026
From 1 valuation models · updated today
Fair value updated Jul 18, 2026, revised from kr 3.55 to kr 0.2800 (−92.1%) since Jun 24, 2026. Share price +3.0% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 0.8000 – kr 1.39 · fair‑value band kr 0.1800 – kr 0.3400 · the kr 0.8600 price screens above the kr 0.2800 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ScandiDos AB (SDOS) currently trades at kr 0.8600, while our model-based Fair Value estimate is kr 0.2800, implying the stock looks roughly 67.4% overvalued today. We read business quality at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, ScandiDos AB generated revenue of 56.9M SEK at a net margin of -7.4%. Revenue declined 23.9% year over year. It earns a return on equity of -9.6%. The balance sheet holds a net cash position of 10.1M SEK. Fundamentals as of Jul 18, 2026
Our scenario range runs from kr 0.1800 (bear case) to kr 0.3400 (bull case); at kr 0.8600, the current price sits above that range. The share trades about 42% below its 52-week high and 1% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -39% fair-value upside, at -67%, SDOS screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
ScandiDos AB (publ), together with its subsidiaries, provides measurement phantoms and software solutions for the quality assurance and validation of dynamic and modulated treatments adopted in clinics in the United States, Europe, Asia, and internationally. The company offers Delta4 products comprising Delta4 Phantom+, Delta4Phantom+MR, Delta4 HexaMotion, Delta4Insight, Delta4DVH Anatomy, Delta4 Machine QA, and Delta4 Statistics Module for the quality assurance in advanced radiation therapy techniques, such as VMAT, RapidArc, IMRT, and Tomotherapy. It sells its products directly to consumers and through distributors. ScandiDos AB (publ) was founded in 2001 and is headquartered in Uppsala, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ScandiDos AB reported revenue of kr 60.4M in FY2025 versus kr 60.0M in FY2021, a compound +0.2%/yr. Reported net income was −kr 14.6M in FY2025.
Is SDOS fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,228 MXN | -23% |
| Stryker Corporation SYK | $305.66 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$203.91 | R$27.47 | -87% |
| Boston Scientific Corporation B1SX34 | R$220.45 | R$34.74 | -84% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
| DexCom, Inc DXCM | $72.59 | $39.33 | -46% |
| GE HealthCare Technologies Inc GEHC | $63.76 | $44.97 | -29% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥143.50 | ¥111.50 | -22% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ScandiDos AB (SDOS) undervalued?
What is the fair value of SDOS?
What is the quality score of SDOS?
What is the revenue of ScandiDos AB (SDOS)?
What is the net profit margin of SDOS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when ScandiDos AB reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of ScandiDos AB materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.